The European Commission approved Zynquista (sotagliflozin) as a new treatment for people with type 1 diabetes. Zynquista is an oral tablet which prevents the SGLT-1 and SGLT-2 proteins that impact how the intestines and kidneys absorb and glucose that will result in better diabetes control.
Sanofi is collaborating the drug with Lexicon Pharmaceuticals. It has been designed for adults who have a body mass index of 27 kg/m2 and struggle to keep control of their blood sugar levels.
A slew of clinical studies was performed on 3,000 people, and the results showed Zynquista helped in decreasing average blood sugar levels, body weight, and blood pressure and improved time within the target blood glucose range.
Dr John Reed, Sanofi's global head of research and development apprised the dual mechanism of action of Zynquista. The drug proffers significant treatment benefits for adults with type 1 diabetes that is, decreasing blood sugar reabsorption in the kidneys through SGLT-2 inhibition and deferring dietary sugar absorption via local SGLT-1 inhibition in the intestinal tract.
The European thumbs up Zynquista that trail an approval of dapagliflozin for type 1 diabetes in February. Dapagliflozin, marketed as Forxiga, became the first oral medication to get European support for treatment in adults with type 1 diabetes. Dapagliflozin comes into use when insulin solely does not provide adequate control of blood glucose. Forxiga (dapagliflozin) in an SGLT-2 inhibitor medication.
Sotagliflozin indicated that it could decrease the glycemic variability in people. Diabetes experts are progressively accentuating time in range as a vital measure than glycated haemoglobin.
"A plethora of people living with type 1 diabetes who are obese, the drug- Zynquista will proffer a new treatment option. The physicians can now reckon in combination with insulin therapy for suitable patients."